负担
发表于 2025-3-25 05:30:58
http://reply.papertrans.cn/67/6660/665924/665924_21.png
全神贯注于
发表于 2025-3-25 08:36:27
Platelet Inhibitors and the Prevention of Stroked the progression of the atherosclerotic lesions of the vessel wall. A great variety of laboratory tests have shown enhanced platelet function in patients with vascular disease, e.g., enhanced platelet aggregation, formation of “in vivo aggregates,” shortening of platelet life span, and liberation o
strain
发表于 2025-3-25 14:56:59
http://reply.papertrans.cn/67/6660/665924/665924_23.png
幻影
发表于 2025-3-25 17:33:08
Risk and Benefit of Anticoagulation in Patients with Acute Hemispheric Infarctions: Preliminary Resuo have had cardiogenic brain embolism experience reinfarction within a 2-week period after the initial attack (Table 1). This rate is similar to that for most cardiac sources of emboli (Table 2) except for nonvalvular atrial fibrillation, which seems to be characterized by a lower risk of
Flat-Feet
发表于 2025-3-25 21:26:57
http://reply.papertrans.cn/67/6660/665924/665924_25.png
Musket
发表于 2025-3-26 02:26:40
http://reply.papertrans.cn/67/6660/665924/665924_26.png
LANCE
发表于 2025-3-26 04:30:05
Effect of Nimodipine on the Cerebral Circulation and Acute Ischemic Strokes the “final common pathway”, resulting in catabolism and cell necrosis due to calcium overload. Treatment with calcium entry blockers, therefore, may be a new approach to arresting, and possibly preventing, destruction of cerebral tissue in stroke patients. The calcium entry blocker nimodipine was
自爱
发表于 2025-3-26 09:06:42
http://reply.papertrans.cn/67/6660/665924/665924_28.png
易于出错
发表于 2025-3-26 15:12:56
Effect of Nimodipine on the Cerebral Circulation and Acute Ischemic Strokemulticenter study was conducted. The data from this study strongly suggest that patients with acute ischemic stroke benefit from treatment with 120 mg nimodipine, started with 24 h after onset, combined with a “Standard” treatment, e. g., hemodilution by low molecular weight dextran. The conclusion
加剧
发表于 2025-3-26 19:06:59
invaluable to both researchers and clinicians studying the development of and treating patients with Alzheimer’s Disease.978-1-4939-6034-7978-1-62703-598-9Series ISSN 2197-7224 Series E-ISSN 2197-7232